SCHEMBL2177615

SCHEMBL2177615

CCN(CC)C[C@H](O)COc1cc2nccc(Oc3ccc(NC(=O)NC)c(Cl)c3)c2cc1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.47
PDGFRA P16234 8/20 0.46
FLT1 P17948 4/20 0.46
FLT4 P35916 4/20 0.46
FGFR1 P11362 4/20 0.46
KIT P10721 4/20 0.46
RET P07949 3/20 0.46
MET P08581 3/20 0.46
RIPK2 O43353 2/20 0.46
STK10 O94804 2/20 0.46
ABL1 P00519 2/20 0.46
PDGFRB P09619 2/20 0.46
BCR P11274 2/20 0.46
EPHB2 P29323 2/20 0.46
SLC6A3 Q01959 2/20 0.46
DDR1 Q08345 2/20 0.46
MAP4K2 Q12851 2/20 0.46
PTK6 Q13882 2/20 0.46
DDR2 Q16832 2/20 0.46
AURKB Q96GD4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177612 1.00 KDR (0.47) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1897135 0.93 KDR (0.46) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1897137 0.93 KDR (0.46) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL12673523 0.92 KDR (0.46) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1891662 0.91 FGFR4 (0.57) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1891658 0.91 FGFR4 (0.57) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL14693153 0.90 AXL (0.39) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1250646 0.89 KDR (0.49) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1250643 0.89 KDR (0.49) KDRPDGFRAFLT1FLT4FGFR1
SCHEMBL1893032 0.87 KDR (0.48) KDRPDGFRAFLT1FLT4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
EP-1777218-B1 Process for the preparation of 4-phenoxy quinoline derivatives EISAI R&D MAN CO LTD (JP) 2008-12-31 EP disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
EP-1777218-A1 Process for the preparation of 4-phenoxy quinoline derivatives Eisai R&D Management Co., Ltd. (JP) 2007-04-25 EP disclosed
EP-1415987-B1 NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS EISAI R&D MAN CO LTD (JP) 2007-02-28 EP disclosed
US-20060247259-A1 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-11-02 US disclosed
US-20060160832-A1 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-07-20 US disclosed
EP-1506962-A2 Nitrogen-containing aromatic heterocycles Eisai Co. Ltd. (JP) 2005-02-16 EP disclosed
EP-1415987-A1 NITROGENOUS AROMATIC RING COMPOUNDS Eisai Co., Ltd. (JP) 2004-05-06 EP disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives GNG2, GCG, FRG1 KDR 2687/4885PDGFRA 3131/4885FLT1 1368/4885
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R KDR 22/4885PDGFRA 1572/4885FLT1 4/4885
US-20060247259-A1 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective UGGT1, FLT1, GCG KDR 60/4885PDGFRA 1743/4885FLT1 2/4885
US-20060160832-A1 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective UGGT1, FLT1, GCG KDR 60/4885PDGFRA 1743/4885FLT1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.